Meeting
2014 ASCO Annual Meeting
Phase IB trial of carboxyamidotriazole orotate (CTO) and temozolomide for recurrent malignant glioma (MG): A novel mechanism for modulation of multiple oncogenic pathways.
Authors
Antonio Marcilio Padula Omuro
Memorial Sloan-Kettering Cancer Center, New York, NY
Antonio Marcilio Padula Omuro , Thomas Joseph Kaley , Elena Pentsova , Lisa Marie DeAngelis , Walter John Urba , Matthew Hiram Taylor , Barry Douglas Anderson , Greg Gorman , Sean McLean , Rashida A. Karmali
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01107522
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2071)
DOI
10.1200/jco.2014.32.15_suppl.2071
Abstract #
2071
Poster Bd #
36
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.
First Author: Annick Desjardins
Poster
2013 ASCO Annual Meeting
Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma or progressive secondary brain tumor.
First Author: James D. Peyton
Poster
2019 ASCO Annual Meeting
Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent malignant glioma.
First Author: Martin Kelly Nicholas
Poster
2016 ASCO Annual Meeting
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).
First Author: Martin J. Van Den Bent